The long-term safety and tolerability of high-dose interferon β-1a in relapsing-remitting multiple sclerosis: 4-Year data from the PRISMS study

European Journal of Neurology

Volumn 12, Issue 8, 2005, Pages 649-656

  Gold, R ^a   Rieckmann, P ^b   Chang, P ^c   Abdalla, J ^d,e  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c EMD SERONO INC   (United States)

^d Serono International SA   (Switzerland)

^e TEVA Neuroscience   (United States)

Author keywords

Interferon beta; Long term safety tolerability; Multiple sclerosis; PRISMS

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; BETA1A INTERFERON;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; FLU LIKE SYNDROME; GRANULOCYTOPENIA; HEADACHE; HUMAN; INFLAMMATION; INJECTION SITE REACTION; LEUKOPENIA; LONG TERM CARE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; MYALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RHINITIS; RIGOR; SUICIDE ATTEMPT;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; DEPRESSION; DISABILITY EVALUATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG TOLERANCE; EPILEPSY; FEMALE; HEADACHE; HUMANS; INTERFERON-BETA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PLACEBOS; TIME FACTORS; TREATMENT OUTCOME;

EID: 23644459519     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2005.01083.x     Document Type: Article

References (10)

1. Durelli L, Ferrero B, Oggero A et al. (2001). Liver and thyroid function and autoimmunity during interferon-beta 1b treatment for MS. Neurology 57:1363-1370.
2. Francis GS, Grumser Y, Alteri E et al. (2003). Hepatic reactions during treatment of multiple sclerosis with interferon-β-1a: incidence and clinical significance. Drug Saf 26:815-827.
3. IFNB Multiple Sclerosis Study Group (1993). Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomised, double-blind, placebo-controlled trial. Neurology 43:655-661.
4. IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group (1995). Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomised controlled trial. Neurology 45:1277-1285.
5. Jacobs LD, Cookfair DL, Rudick RA et al. (1996). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39:285-294.
6. Li DH, Paty DW (UBC MS/MRI Analysis Research Group, PRISMS Study Group) (1999). Magnetic resonance imaging results of the PRISMS trial: a randomised, double-blind, placebo-controlled study of interferon-β1a in relapsing-remitting multiple sclerosis. Ann Neurol 4:197-206.
7. Patten SB, Metz LM (2001). Interferon beta-1a and depression in relapsing-remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial. Mult Scler 7:243-248.
8. PRISMS Study Group (1998). Randomised, double-blind placebo-controlled study of interferon β-1a in relapsing-remitting multiple sclerosis. Lancet 352:1498-1504.
9. PRISMS Study Group (2001). PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 56:1628-1636.
10. Walther EU, Hohlfeld R (1999). Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology 53:1622-1627.